Understanding The Nicotinic Alpha4beta2 Receptor (P16176)

Target Name: Nicotinic alpha4beta2 receptor

NCBI ID: P16176

Nicotinic alpha4beta2 receptor

Other Name(s): alpha4beta2 receptor | alpha4beta2 nAChR | Alpha-4 beta-2 nicotinic receptor

Understanding The Nicotinic Alpha4beta2 Receptor

The Nicotinic alpha4beta2 receptor (alpha4beta2 receptor) is a G protein-coupled receptor (GPCR) that is expressed in various tissues and cells throughout the body. It is involved in various physiological processes, including neurotransmission, pain perception, and body temperature regulation. Despite its importance, the alpha4beta2 receptor has also been identified as a potential drug target and biomarker.

The alpha4beta2 receptor is a member of the GPCR family, which includes over 700 different receptors that play a critical role in various cellular processes. The alpha4beta2 receptor is one of the best-studied GPCRs, and its function has been extensively characterized.

The alpha4beta2 receptor is a transmembrane receptor that is located at the end of the pre-synaptic dendrites of neurons. It consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The transmembrane domain is the region of the receptor that is involved in the interaction with intracellular signaling molecules.

The alpha4beta2 receptor is involved in the regulation of a wide range of physiological processes, including neurotransmission, pain perception, and body temperature regulation. It is involved in the neurotransmitter release of several neurotransmitters, including dopamine, serotonin, and GABA. It is also involved in the modulation of pain perception and body temperature.

In addition to its role in neurotransmission, the alpha4beta2 receptor is also being targeted as a potential drug target. The alpha4beta2 receptor has been shown to be a strong predictor of therapeutic response to various neurotransmitter antagonist drugs, including those used to treat depression, anxiety, and pain.

The alpha4beta2 receptor is also being used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. For example, alpha4beta2 receptor levels have been shown to be elevated in the brains of individuals with Alzheimer's disease, and it is also a potential biomarker for cancer.

Despite its potential as a drug target and biomarker, the alpha4beta2 receptor is still not well understood. The functions of the alpha4beta2 receptor are still being investigated, and much of its biology is still unknown. However, the study of the alpha4beta2 receptor is an important area of research, as it has the potential to contribute to the development of new treatments for a wide range of diseases.

In conclusion, the Nicotinic alpha4beta2 receptor is a GPCR that is involved in various physiological processes throughout the body. It is a potential drug target and biomarker, and its functions are still being investigated. Further research is needed to fully understand the role of the alpha4beta2 receptor and its potential as a therapeutic target.

Protein Name: Nicotinic Alpha4beta2 Receptor

The "Nicotinic alpha4beta2 receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nicotinic alpha4beta2 receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets